Twist Bioscience Stock Price, News & Analysis

Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Jim Thorburn will present at the Baird 2021 Global Healthcare Conference on September 14 at 4:20 p.m. Eastern Time. This virtual event will be available for live streaming on the company's investor relations website and archived for 30 days post-event. Twist Bioscience specializes in high-quality synthetic DNA production using a proprietary silicon-based platform, serving multiple industries, including healthcare and agriculture.

Twist Bioscience Corporation (NASDAQ: TWST) announced that CFO Jim Thorburn and CCO Patrick Finn will host a fireside chat at the UBS Genomics 2.0 and Medtech Innovations Summit on August 11th at 2:00 p.m. P.T. in Laguna Beach, California. The event will be webcast live and available for replay for 30 days after the chat. Twist Bioscience is a leader in synthetic biology, utilizing its unique silicon-based platform to produce a variety of synthetic DNA products for healthcare, agriculture, and research sectors.

Twist Bioscience (TWST) reported strong third-quarter results for fiscal 2021, ending June 30, with total revenues of $35.0 million, a 65% increase year-over-year. Orders reached $39.1 million, up from $24.7 million in Q3 2020. Despite a net loss of $40.0 million, or $0.82 per share, the company increased its revenue guidance, driven by growth in DNA synthesis and NGS tools. Key developments included the acquisition of iGenomX and advancements in NGS workflows, supporting a rising customer base of approximately 1,800 clients.

Twist Bioscience Corporation (NASDAQ: TWST) has appointed Dr. Melissa Starovasnik to its board of directors. With nearly 30 years of experience in protein and antibody drug discovery, including significant roles at Genentech, Dr. Starovasnik is expected to provide valuable strategic guidance for Twist's biopharma expansion. CEO Emily M. Leproust highlighted her expertise as crucial for leveraging Twist's DNA platform to support a diverse customer base. Dr. Starovasnik aims to enhance collaboration with Twist's leadership to capitalize on biopharmaceutical opportunities and further strengthen the company's market position.

Twist Bioscience (Nasdaq: TWST) and MOLCURE Inc. have announced a collaboration that resulted in the generation of potent antibodies for an undisclosed oncology target, enhancing Twist's internal pipeline. This partnership leverages Twist's antibody discovery and optimization technology alongside MOLCURE's AI capabilities. Both companies expressed optimism about the potential advancements in drug discovery from this collaboration. Twist continues to innovate in synthetic biology, aiming for long-term growth across various sectors, including healthcare and agriculture.

Twist Bioscience Corporation (Nasdaq: TWST) has commenced shipping synthetic RNA reference controls for the SARS-CoV-2 Delta variants B.1.617.2 and B.1.617.3, which are swiftly spreading globally. CEO Emily M. Leproust emphasized the ongoing pandemic challenges and the company’s commitment to offering essential synthetic DNA and RNA products aimed at combating COVID-19. Twist's offerings include NGS assays and a broad range of infectious disease panels. The synthetic controls are sequence-verified and cover the entire viral genome, addressing the evolution of SARS-CoV-2.

Twist Bioscience Corporation (NASDAQ: TWST) will announce its fiscal 2021 third-quarter financial results on August 6, 2021, before market open. A conference call is scheduled for 8:00 a.m. ET to discuss the results and provide a business update. Twist, known for its innovative synthetic DNA technology, is focused on various sectors including healthcare and agriculture. Investors can access the financial results via the Investor Relations section of the company's website.

Twist Bioscience Corporation (Nasdaq: TWST) has announced the acquisition of iGenomX for $35 million, which includes $500,000 in cash and $29.5 million in stock, plus a $5 million contingent payment. This strategic acquisition aims to enhance Twist's multiplex sequencing capabilities and facilitate customer transitions from SNP microarrays to next-generation sequencing (NGS). Expected revenue from iGenomX is projected at $4-6 million for fiscal 2023, with minimal impact on the company’s expenses in fiscal 2021 and 2022.

Dovetail Genomics, a leader in genomic solutions, has launched its new capture Hi-C technology, which includes two targeted enrichment panels for human and mouse samples. These products enable analysis of chromatin topology surrounding 80,000 gene promoters, significantly reducing the sequencing burden by over 90%. The collaboration with Twist Bioscience enhances this offering with its proprietary enrichment technology, promising advancements in research addressing gene expression. CEO statements highlight the potential for new biomarkers and improved understanding of disease mechanisms.